{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-006327","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.036540+00:00","generated_at":"2026-05-16T11:29:09.753253+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed","bullets":["Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.","Common stock to trade under symbol KYNB on Nasdaq at market open Jan 8, 2026; CUSIP unchanged.","CEO cites sale of FibroGen China, payoff of term loan, and cash runway extended into 2028.","FG-3246 Phase 2 monotherapy interim results expected H2 2026; topline Phase 1b/2 combo at ASCO GU Q1 2026.","Roxadustat granted FDA Orphan Drug Designation for MDS; pivotal Phase 3 protocol submitted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-006327","json":"https://secwatch.observer/filing/0001193125-26-006327.json","markdown":"https://secwatch.observer/filing/0001193125-26-006327.md","text":"https://secwatch.observer/filing/0001193125-26-006327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/fgen-20260107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:29:09.753253+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cdf713694d65e36548c2b695c3ced91598752fd","claim":"KYNTRA BIO, INC.: Amended certificate of incorporation to change company name from FibroGen, Inc. to Kyntra Bio, Inc (effective 2026-01-07).","evidence_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","confidence":0.9},{"claim_id":"2e432c168d52cef62c8cde2aa70caa84647445a0","claim":"KYNTRA BIO, INC.: Amended bylaws solely to update the title to reflect the company's new name, Kyntra Bio, Inc (effective 2026-01-07).","evidence_excerpt":"The Board also approved the amendment of the Company’s Bylaws, effective at 4:30 p.m. Eastern Time on January 7, 2026, solely to update the title of the Bylaws to reflect the Company’s new name, Kyntra Bio, Inc.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001104659-26-068521","ticker":"FDXF","company_name":"FedEx Freight Holding Company, Inc.","filed_at":"2026-06-01T10:46:03+00:00","headline":"FedEx Freight completes spin-off from FedEx; $600M drawn, new board and executives appointed","event_type":"other_material","sec_items":["1.01","2.03","3.03","5.03","5.01","5.02","5.05","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068521","json":"https://secwatch.observer/filing/0001104659-26-068521.json","markdown":"https://secwatch.observer/filing/0001104659-26-068521.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/tm2615735d2_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"As of 9:30 a.m., Eastern Time, on May 27, 2026, the certificate of incorporation of the Company was amended by the certificate of amendment to the certificate of incorporation of the Company (the “Certificate of Amendment”), which, among other things, (i) created and authorized 500,000,000 shares of the Company’s common stock, par value $0.10 per share (the “Common Stock”), and (ii) converted the total number of shares of the Common Stock issued and outstanding into a number of validly issued, fully paid, and non-assessable shares of the Common Stock authorized for issuance pursuant to the Certificate of Amendment equal to 149,505,248.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2082247/000110465926068521/0001104659-26-068521-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001703056-26-000078","ticker":"ADT","company_name":"ADT Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan","event_type":"other_material","sec_items":["5.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001703056-26-000078","json":"https://secwatch.observer/filing/0001703056-26-000078.json","markdown":"https://secwatch.observer/filing/0001703056-26-000078.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/adt-20260504.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1703056/000170305626000078/0001703056-26-000078-index.htm"}},{"accession":"0001193125-26-207628","ticker":"BNZI","company_name":"Banzai International, Inc.","filed_at":"2026-05-06T23:59:59+00:00","headline":"Banzai announces 1-for-20 reverse stock split effective May 8, 2026 to maintain Nasdaq compliance","event_type":"other_material","sec_items":["3.03","5.03","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-207628","json":"https://secwatch.observer/filing/0001193125-26-207628.json","markdown":"https://secwatch.observer/filing/0001193125-26-207628.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526207628/0001193125-26-207628-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526207628/bnzi-20260505.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On April 28, 2026, the Company filed a Certificate of Amendment to its COI with the Secretary of State of Delaware (the “Certificate of Amendment”), for the Reverse Stock Split at a ratio of 1-for-20.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1826011/000119312526207628/0001193125-26-207628-index.htm"}},{"accession":"0001213900-26-052459","ticker":"QLEP","company_name":"Quantum Leap Acquisition Corp","filed_at":"2026-05-06T23:59:59+00:00","headline":"Quantum Leap Acquisition Corp closes $200M SPAC IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-052459","json":"https://secwatch.observer/filing/0001213900-26-052459.json","markdown":"https://secwatch.observer/filing/0001213900-26-052459.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/ea0289253-8k_quantum.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"In connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies. The Amended and Restated Memorandum and Articles of Association have an effective date of April 29, 2026, being the date on which the special resolution to adopt the Amended and Restated Memorandum and Articles of Association was passed.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2102155/000121390026052459/0001213900-26-052459-index.htm"}},{"accession":"0001829126-26-004565","ticker":"MCAH","company_name":"Mountain Crest Acquisition 6 Corp.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Mountain Crest Acquisition 6 Corp. closes $60M IPO; units start trading April 30","event_type":"other_material","sec_items":["1.01","3.02","5.03","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004565","json":"https://secwatch.observer/filing/0001829126-26-004565.json","markdown":"https://secwatch.observer/filing/0001829126-26-004565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/mountaincrest6_8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On April 29, 2026, in connection with the IPO, the Company filed its Amended and Restated Memorandum and Articles of Association, as described in the Registration Statement, with the Registry of Corporate Affairs of British Virgin Islands.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2109876/000182912626004565/0001829126-26-004565-index.htm"}},{"accession":"0001193125-26-203988","ticker":"COAG","company_name":"Hemab Therapeutics Holdings, Inc.","filed_at":"2026-05-04T23:59:59+00:00","headline":"Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M","event_type":"other_material","sec_items":["5.03","8.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: governance_change","same SEC item: 5.03, 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-203988","json":"https://secwatch.observer/filing/0001193125-26-203988.json","markdown":"https://secwatch.observer/filing/0001193125-26-203988.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/d149100d8k.htm"},"side_by_side_evidence":{"fact_type":"governance_change","source_excerpt":"On December 29, 2025, FibroGen, Inc. (the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware changing the name of the Company from “FibroGen, Inc.” to “Kyntra Bio, Inc.” The Certificate of Amendment shall be effective at 4:30 p.m. Eastern Time on January 7, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526006327/0001193125-26-006327-index.htm","comparable_excerpt":"On May 4, 2026, Hemab Therapeutics Holdings, Inc. (the “Company”) filed a restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Company’s initial public offering of common stock (the “IPO”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2114044/000119312526203988/0001193125-26-203988-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}